PE20071100A1 - Derivados de azepinoindol como agentes farmaceuticos - Google Patents
Derivados de azepinoindol como agentes farmaceuticosInfo
- Publication number
- PE20071100A1 PE20071100A1 PE2006001614A PE2006001614A PE20071100A1 PE 20071100 A1 PE20071100 A1 PE 20071100A1 PE 2006001614 A PE2006001614 A PE 2006001614A PE 2006001614 A PE2006001614 A PE 2006001614A PE 20071100 A1 PE20071100 A1 PE 20071100A1
- Authority
- PE
- Peru
- Prior art keywords
- substituted
- alkyl
- tetrahidroazepino
- indol
- rental
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DODNE R1 ES -C(J)R11, -C(J)OR11, -C(J)N(R10)(R11); J ES UN ENLACE DIRECTO, NR10; n ES 0-4; R3 ES H, C(O)R9, CON(R11)(R12); R6 Y R7 SON CADA UNO ALQUILO SUSTITUIDO O NO, CICLOALQUILO SUSTITUIDO O NO, CICLOALQUILALQUILO SUSTITUIDO O NO; R8 ES OH, ALQUILO SUSTITUIDO O NO, HALO, HALOALCOXI, HALOALQUILO, ENTRE OTROS; R9 ES ALQUILO SUSTITUIDO O NO, ARALQUILO SUSTITUIDO O NO, ALQUINILO SUSTITUIDO O NO, ENTRE OTROS; R10 ES H, ALQUILO SUSTITUIDO O NO, HETEROCICLILO SUSTITUIDO O NO, ENTRE OTROS; R11 ES H, ALQUILO SUSTITUIDO O NO, ALQUINILO SUSITUIDO O NO, ENTRE OTROS; R12 ES H, ALQUILO SUSTITUIDO O NO, ALQUENILO SUSTITUIDO O NO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-METILETIL 1,1-DIMETIL-3-{[(1S,4S)-5-METIL-2,5-DIAZABICICLO[2.2.1]HEPT-2-IL]CARBONIL}-1,2,3,6-TETRAHIDROAZEPINO[4,5-b]INDOL-5-CARBOXILATO; 1-METILETIL 1,1-DIMETIL-3-({4-[(1-METILPIPERIDIN-4-IL)METIL]PIPERAZIN-1-IL}CARBONIL)-1,2,3,6-TETRAHIDROAZEPINO[4,5-b]INDOL-5-CARBOXILATO; ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES NUCLEARES ESPECIALMENTE FARNESOIDE X UTILES EN EL TRATAMIENTO ATEROSCLEROSIS Y RELACIONADOS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75063405P | 2005-12-15 | 2005-12-15 | |
US75067905P | 2005-12-15 | 2005-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20071100A1 true PE20071100A1 (es) | 2007-12-21 |
Family
ID=37946206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001614A PE20071100A1 (es) | 2005-12-15 | 2006-12-15 | Derivados de azepinoindol como agentes farmaceuticos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090203577A1 (es) |
EP (1) | EP1963331A1 (es) |
JP (2) | JP5420908B2 (es) |
AR (1) | AR058781A1 (es) |
AU (1) | AU2006325815B2 (es) |
BR (1) | BRPI0620156A2 (es) |
CA (1) | CA2633243C (es) |
EC (1) | ECSP088623A (es) |
IL (1) | IL191907A0 (es) |
PE (1) | PE20071100A1 (es) |
RU (1) | RU2008128823A (es) |
TW (1) | TW200745124A (es) |
WO (1) | WO2007070796A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0412262A (pt) * | 2003-07-23 | 2006-09-19 | X Ceptor Therapeutics Inc | derivados de azepina como agentes farmacêuticos |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2240481A1 (en) | 2008-01-11 | 2010-10-20 | Albany Molecular Research, Inc. | (1-azinone) -substituted pyridoindoles as mch antagonists |
EP2518052B1 (de) | 2008-03-27 | 2017-12-20 | Grünenthal GmbH | Substituierte 4-Aminocyclohexan-Derivate |
AU2009228645B2 (en) * | 2008-03-27 | 2013-07-18 | Grunenthal Gmbh | Hydroxymethylcyclohexyl amines |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
WO2010036362A1 (en) * | 2008-09-26 | 2010-04-01 | Wyeth | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
AR074760A1 (es) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
US8637501B2 (en) | 2009-07-01 | 2014-01-28 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof |
WO2011003012A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
TW201139370A (en) | 2009-12-23 | 2011-11-16 | Lundbeck & Co As H | Processes for the manufacture of a pharmaceutically active agent |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
ITRM20100329A1 (it) * | 2010-06-15 | 2011-12-16 | Franco Baldelli | Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
US8993765B2 (en) | 2010-12-21 | 2015-03-31 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
AU2015229072A1 (en) * | 2014-03-13 | 2016-09-29 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
AU2015370588B2 (en) * | 2014-12-22 | 2020-07-16 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
CA2980394A1 (en) * | 2015-03-26 | 2016-09-29 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
WO2017078928A1 (en) * | 2015-11-06 | 2017-05-11 | Salk Institute For Biological Studies | Fxr agonists and methods for making and using |
WO2017143134A1 (en) * | 2016-02-19 | 2017-08-24 | Alios Biopharma, Inc. | Fxr modulators and methods of their use |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
KR102269305B1 (ko) | 2016-06-13 | 2021-06-25 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
RS62711B1 (sr) | 2017-04-12 | 2022-01-31 | Il Dong Pharma | Derivati izoksazola kao agonisti nuklearnih receptora i njihova upotreba |
DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | Fxrアゴニストの固体形態 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2663935A1 (fr) * | 1990-06-27 | 1992-01-03 | Adir | Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
MY122278A (en) * | 1999-07-19 | 2006-04-29 | Upjohn Co | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
BRPI0412262A (pt) * | 2003-07-23 | 2006-09-19 | X Ceptor Therapeutics Inc | derivados de azepina como agentes farmacêuticos |
-
2006
- 2006-12-12 CA CA2633243A patent/CA2633243C/en not_active Expired - Fee Related
- 2006-12-12 JP JP2008545937A patent/JP5420908B2/ja active Active
- 2006-12-12 EP EP06846570A patent/EP1963331A1/en not_active Withdrawn
- 2006-12-12 US US12/096,961 patent/US20090203577A1/en not_active Abandoned
- 2006-12-12 AU AU2006325815A patent/AU2006325815B2/en not_active Ceased
- 2006-12-12 RU RU2008128823/04A patent/RU2008128823A/ru not_active Application Discontinuation
- 2006-12-12 WO PCT/US2006/061928 patent/WO2007070796A1/en active Application Filing
- 2006-12-13 TW TW095146559A patent/TW200745124A/zh unknown
- 2006-12-15 AR ARP060105554A patent/AR058781A1/es unknown
- 2006-12-15 BR BRPI0620156-3A patent/BRPI0620156A2/pt not_active IP Right Cessation
- 2006-12-15 PE PE2006001614A patent/PE20071100A1/es not_active Application Discontinuation
-
2008
- 2008-06-03 IL IL191907A patent/IL191907A0/en unknown
- 2008-07-14 EC EC2008008623A patent/ECSP088623A/es unknown
-
2013
- 2013-09-17 JP JP2013191865A patent/JP2014028829A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2014028829A (ja) | 2014-02-13 |
CA2633243C (en) | 2014-05-27 |
EP1963331A1 (en) | 2008-09-03 |
US20090203577A1 (en) | 2009-08-13 |
RU2008128823A (ru) | 2010-01-20 |
AU2006325815A1 (en) | 2007-06-21 |
CA2633243A1 (en) | 2007-06-21 |
TW200745124A (en) | 2007-12-16 |
IL191907A0 (en) | 2008-12-29 |
AU2006325815B2 (en) | 2012-07-05 |
AR058781A1 (es) | 2008-02-20 |
JP5420908B2 (ja) | 2014-02-19 |
JP2009519964A (ja) | 2009-05-21 |
ECSP088623A (es) | 2008-08-29 |
BRPI0620156A2 (pt) | 2011-12-20 |
WO2007070796A1 (en) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20071100A1 (es) | Derivados de azepinoindol como agentes farmaceuticos | |
PE20211911A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
PE20060555A1 (es) | Derivados de pirrol-oxindol como moduladores del receptor de progesterona | |
PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
AR065985A1 (es) | Derivados de arilisoxazolina,composiciones que los contienen y usos de los mismos como agentes insecticidas y acaricidas. | |
AR066144A1 (es) | Derivados de aril pirrolidinas utiles como insecticidas y/o acaricidas y composiciones insecticidas que los contienen. | |
PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
PE20010544A1 (es) | Derivados de mutilina utiles como agentes antibacterianos | |
AR056317A1 (es) | Compuestos de oxindol y composicion farmaceutica | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
PE20080839A1 (es) | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas | |
PE20051141A1 (es) | Inhibidores de la polimerasa viral | |
AR051461A1 (es) | Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
AR044795A1 (es) | Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
PE20091381A1 (es) | Inhibidores del virus de la hepatitis c | |
AR072576A1 (es) | Metodo para la represion de malezas en un cesped | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR076838A1 (es) | Sulfonamidas nematocidas | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20141228A1 (es) | Derivados de pirrolopirimidina y purina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FX | Voluntary withdrawal |